An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

ADHD Clinical Trial

— A-GAMES  

Official title:

An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms - A Prospective, Multicenter, Open Label, Single Arm, Intervention Study to Assess Efficacy and Safety of an At-home, Game-based Digital Therapy for Treating Clinical Symptoms of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05805176
• Other study ID #: CIP-014
• Status: Recruiting
• Phase: N/A
• Start date: April 15, 2023
• Est. completion date: June 2025

Study information

• Verified date: March 2024
• Source: Lumos Labs, Inc.
• Contact: Bob Schafer, PhD
• Phone: (530) 746-8565
• Email: bschafer[@]lumoslabs.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 194
• Est. completion date: June 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• 22-55 years of age (Cohort I) or 18-21 years of age (Cohort II)

• Confirmed ADHD diagnosis, combined or inattentive type, at Screening based on DSM-5 criteria and established via the MINI-Adult, administered by a trained clinician

• Baseline total score on the DSM 5 Inattentive Symptoms, DSM 5 Hyperactive - Impulsive Symptoms and ADHD Index subscales of the Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) =24

• Current, stable use of an FDA approved pharmacological treatment for ADHD for at least 4 weeks prior to screening, but ADHD condition inadequately managed by that medication

• Ability to understand and speak English, follow written and verbal instructions (English), as assessed by the PI and/or Study Coordinator, and give informed consent (English)

• Have ability to connect wireless devices to a functional wireless network daily

• Have access to a computer or smart device (e.g., phone, tablet) with internet access and a Google Chrome web browser

• Ability to comply with all the testing and study requirements

Exclusion Criteria:

• Unstable/uncontrolled, comorbid psychiatric diagnosis, based on clinical interviewing, with significant current active symptoms including but not limited to posttraumatic stress disorder, schizophrenia spectrum and other psychotic disorders, bipolar disorder, autism spectrum disorder, severe obsessive-compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments

• Inadequate IQ to participate in the study as estimated by Investigator (i.e., inability to read/understand the informed consent; inability to understand how the device and therapy (games) work)

• PHQ-9 scores =16

• Have previously been assessed by TOVA for potential enrollment in a clinical trial.

• Have previously used a videogame-like digital therapy (e.g., Akili EndeavorRxTM) OR within the last three years, have used a cognitive or brain training platform (e.g., Peak, Brain HQ, Lumosity, Atentiv) for more than two weeks duration

• Known sensitivity to playing video games, such as headaches, dizziness, nausea

• Initiation within the last 4 weeks of behavioral therapy or neurofeedback, or planned initiation during the study. Patients who have been in behavior therapy or neurofeedback consistently for more than 4 weeks may participate provided their routine is unchanged during the course of the study. Patients planning on changing or initiating behavior therapy or neurofeedback during the course of the study will be excluded

• Patient is currently considered a suicide risk in the opinion of the Investigator, as measured by C-SSRS at screening (i.e., score of 4 or 5 on C-SSRS)

• Motor condition (e.g., physical deformity of the hands/arms; protheses) that prevents game playing as observed by the Investigator

• Recent history (within the past 12 months) of suspected alcohol or substance abuse or dependence

• Positive urine drug screen

• History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy

• Visual acuity that cannot be corrected that prevents or negatively impacts game playing as observed by the Investigator

• Any use of psychoactive drugs (other than ADHD medication) that in the opinion of the Investigator may confound study data/assessments

• Has participated in a clinical trial within 90 days prior to screening

• Has a family member or close friend/associate also enrolled/currently participating in the same study

• Any other condition that in the opinion of the Investigator may confound study data/assessments

Related Conditions & MeSH terms

• ADHD
• Attention Deficit Disorder with Hyperactivity

Intervention

Device:
• ADHD Therapy
investigational game-play therapy

Locations

Country	Name	City	State
United States	Hassman Research Institute	Berlin	New Jersey
United States	Midwest Research Group	Brentwood	Missouri
United States	CNS Healthcare of Jacksonville	Jacksonville	Florida
United States	Accel Clinical Research Sites	Lakeland	Florida
United States	Rochester Center for Behavioral Medicine (RCBM)	Rochester Hills	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Lumos Labs, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) Inattentive Symptoms subscale	The Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) has 66 items with multiple subscales.	Study Day 0 to Study Day 63
Secondary	Adult ADHD Self-Report Scale (ASRS) Inattentive Symptoms Subscale	The World Health Organization Adult Self-Report Scale (ASRS) symptom checklist is an 18-item tool to screen for probable ADHD in adults. The ASRS checklist asks respondents to indicate how they have felt and conducted themselves over the past 6 months in terms of frequency of inattention or hyperactivity symptoms, which are rated from 0 ("never") to 4 ("very often"). The checklist is divided into two parts and results in a "Part A" inattention subscore (range 0-36), a "Part B" hyperactivity/ impulsivity subscore (range 0-36), and a total score based on the full scale (range 0-72).	Study Day 0 to Study Day 63
Secondary	Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) ADHD Symptoms Total subscale	The Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) has 66 items with multiple subscales.	Study Day 0 to Study Day 63
Secondary	Sheehan Disability Scale (SDS)	The Sheehan Disability Scale is a five-item, self-rated questionnaire designed to measure the extent to which a patient's disability due to an illness or health problem interferes with work/school, social life/leisure activities, and family life/home responsibilities.	Study Day 0 to Study Day 63